Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Rochester Medical

This article was originally published in The Gray Sheet

Executive Summary

Rochester Medical: Randomized, 400 patient clinical study conducted at the University of Wisconsin, Madison, shows the firm's nitrofurazone-impregnated antibacterial Foley catheter is associated with a lower incidence of catheter-related bacterial urinary tract infections than non-medicated catheters in patients catheterized from one to seven days. The company, which expects to submit a 510(k) for the device within the next several months, claims that patients with non-medicated catheters had three times the rate of bacterial infections. "No adverse reactions were seen" with the device, said lead investigator Dennis Make, MD, University of Wisconsin Medical School, Madison, Wisconsin...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel